

Table SI. Association of subcellular RAD51 expression with clinicopathological characteristics in patients with breast cancer (n=148).

Variable	Total	Subcellular RAD51 expression				P-value
		cyto ^{low} /nu ^{high} (n=38)	cyto ^{high} /nu ^{high} (n=18)	cyto ^{low} /nu ^{low} (n=46)	cyto ^{high} /nu ^{low} (n=46)	
Stage						0.001
I	51 (34.5)	19 (50.0)	10 (55.6)	16 (34.8)	6 (13.0)	
II	61 (41.2)	10 (26.3)	7 (38.9)	23 (50.0)	21 (45.7)	
III/IV	36 (24.3)	9 (23.7)	1 (5.5)	7 (15.2)	19 (41.3)	
Grade						0.494
1	12 (8.1)	4 (10.5)	1 (5.5)	5 (10.9)	2 (4.3)	
2	96 (64.9)	22 (57.9)	10 (55.6)	33 (71.7)	31 (67.4)	
3	40 (27.0)	12 (31.6)	7 (38.9)	8 (17.4)	13 (28.3)	
Age, years						0.118
≤50	74 (50.0)	20 (52.6)	13 (72.2)	21 (45.7)	20 (43.5)	
>50	74 (50.0)	18 (47.4)	5 (27.8)	25 (54.3)	26 (56.5)	
BMI, kg/m ²						0.718
≤24	81 (54.7)	23 (60.5)	11 (61.1)	23 (50.0)	24 (52.2)	
>24	67 (45.3)	15 (39.5)	7 (38.9)	23 (50.0)	22 (47.8)	
Tumor size, cm						0.022
<2	79 (53.4)	26 (68.4)	11 (61.1)	25 (54.4)	17 (37.0)	
2-5	55 (37.2)	9 (23.7)	7 (38.9)	19 (41.3)	20 (43.5)	
>5	14 (9.4)	3 (7.9)	0 (0.0)	2 (4.3)	9 (19.5)	
LN metastasis						0.001
No	87 (58.8)	25 (35.8)	17 (94.4)	27 (58.7)	18 (39.1)	
Yes	61 (41.2)	13 (34.2)	1 (5.6)	19 (41.3)	28 (60.9)	
ER status						0.634
ER ⁻	57 (38.5)	14 (36.8)	7 (38.9)	15 (32.6)	21 (45.7)	
ER ⁺	91 (61.5)	24 (63.2)	11 (61.1)	31 (67.4)	25 (54.3)	
PR status						0.489
PR ⁻	68 (45.9)	15 (39.5)	10 (55.6)	19 (41.3)	24 (52.2)	
PR ⁺	80 (54.1)	23 (60.5)	8 (44.4)	27 (58.7)	22 (47.8)	
HER2 status						0.791
HER2 ⁻	103 (69.6)	26 (68.4)	11 (61.1)	34 (73.9)	32 (69.6)	
HER2 ⁺	45 (30.4)	12 (31.6)	7 (38.9)	12 (26.1)	14 (30.4)	

Values are expressed as n (%). The P-values were calculated using the χ^2 test. BMI, body mass index; cyto, cytoplasmic; ER, estrogen receptor; HER2, epidermal growth factor receptor 2; LN, lymph node; n, patient number; nu, nuclear; PR, progesterone receptor.